Logo image of DERM

JOURNEY MEDICAL CORP (DERM) Stock Fundamental Analysis

NASDAQ:DERM - Nasdaq - US48115J1097 - Common Stock - Currency: USD

7.3  +0.1 (+1.39%)

After market: 7.3 0 (0%)

Fundamental Rating

3

Overall DERM gets a fundamental rating of 3 out of 10. We evaluated DERM against 193 industry peers in the Pharmaceuticals industry. DERM may be in some trouble as it scores bad on both profitability and health. DERM has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DERM has reported negative net income.
DERM had a negative operating cash flow in the past year.
In the past 5 years DERM reported 4 times negative net income.
In multiple years DERM reported negative operating cash flow during the last 5 years.
DERM Yearly Net Income VS EBIT VS OCF VS FCFDERM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

DERM's Return On Assets of -9.77% is fine compared to the rest of the industry. DERM outperforms 69.43% of its industry peers.
With a Return On Equity value of -38.55%, DERM perfoms like the industry average, outperforming 55.44% of the companies in the same industry.
Industry RankSector Rank
ROA -9.77%
ROE -38.55%
ROIC N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
DERM Yearly ROA, ROE, ROICDERM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

DERM has a better Gross Margin (60.39%) than 69.43% of its industry peers.
In the last couple of years the Gross Margin of DERM has declined.
DERM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
DERM Yearly Profit, Operating, Gross MarginsDERM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DERM has more shares outstanding
The number of shares outstanding for DERM has been increased compared to 5 years ago.
Compared to 1 year ago, DERM has a worse debt to assets ratio.
DERM Yearly Shares OutstandingDERM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DERM Yearly Total Debt VS Total AssetsDERM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

DERM has an Altman-Z score of 0.09. This is a bad value and indicates that DERM is not financially healthy and even has some risk of bankruptcy.
DERM's Altman-Z score of 0.09 is in line compared to the rest of the industry. DERM outperforms 52.33% of its industry peers.
DERM has a Debt/Equity ratio of 1.16. This is a high value indicating a heavy dependency on external financing.
DERM's Debt to Equity ratio of 1.16 is on the low side compared to the rest of the industry. DERM is outperformed by 73.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Altman-Z 0.09
ROIC/WACCN/A
WACC10.19%
DERM Yearly LT Debt VS Equity VS FCFDERM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

DERM has a Current Ratio of 1.34. This is a normal value and indicates that DERM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.34, DERM is not doing good in the industry: 75.65% of the companies in the same industry are doing better.
A Quick Ratio of 1.03 indicates that DERM should not have too much problems paying its short term obligations.
DERM has a worse Quick ratio (1.03) than 75.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.03
DERM Yearly Current Assets VS Current LiabilitesDERM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for DERM have decreased strongly by -378.57% in the last year.
The Revenue for DERM has decreased by -29.69% in the past year. This is quite bad
The Revenue has been growing by 9.96% on average over the past years. This is quite good.
EPS 1Y (TTM)-378.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
Revenue 1Y (TTM)-29.69%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%0.84%

3.2 Future

The Earnings Per Share is expected to grow by 59.20% on average over the next years. This is a very strong growth
DERM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 39.80% yearly.
EPS Next Y74.33%
EPS Next 2Y69.56%
EPS Next 3Y59.2%
EPS Next 5YN/A
Revenue Next Year25.14%
Revenue Next 2Y38.2%
Revenue Next 3Y39.8%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DERM Yearly Revenue VS EstimatesDERM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
DERM Yearly EPS VS EstimatesDERM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 8.18 indicates a reasonable valuation of DERM.
Based on the Price/Forward Earnings ratio, DERM is valued cheaply inside the industry as 88.08% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of DERM to the average of the S&P500 Index (36.52), we can say DERM is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.18
DERM Price Earnings VS Forward Price EarningsDERM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DERM Per share dataDERM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

DERM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as DERM's earnings are expected to grow with 59.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.56%
EPS Next 3Y59.2%

More info and screens

0

5. Dividend

5.1 Amount

DERM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JOURNEY MEDICAL CORP

NASDAQ:DERM (7/17/2025, 8:17:15 PM)

After market: 7.3 0 (0%)

7.3

+0.1 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-12 2025-08-12
Inst Owners29.44%
Inst Owner Change0%
Ins Owners10.53%
Ins Owner Change-0.36%
Market Cap126.29M
Analysts82
Price Target9.95 (36.3%)
Short Float %8.23%
Short Ratio6.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.99%
Min EPS beat(2)25.7%
Max EPS beat(2)58.28%
EPS beat(4)2
Avg EPS beat(4)13.68%
Min EPS beat(4)-16.28%
Max EPS beat(4)58.28%
EPS beat(8)4
Avg EPS beat(8)62.66%
EPS beat(12)4
Avg EPS beat(12)28.75%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-6.06%
Max Revenue beat(2)6.86%
Revenue beat(4)2
Avg Revenue beat(4)1.35%
Min Revenue beat(4)-6.06%
Max Revenue beat(4)6.86%
Revenue beat(8)4
Avg Revenue beat(8)13.71%
Revenue beat(12)4
Avg Revenue beat(12)4.31%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.27%
EPS NQ rev (1m)-21.21%
EPS NQ rev (3m)11.11%
EPS NY rev (1m)6.67%
EPS NY rev (3m)-185.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.18
P/S 2.25
P/FCF N/A
P/OCF N/A
P/B 5.86
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)0.89
Fwd EY12.23%
FCF(TTM)-1.27
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS3.25
BVpS1.25
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.77%
ROE -38.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.39%
FCFM N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score2
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.03
Altman-Z 0.09
F-Score2
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-378.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.04%
EPS Next Y74.33%
EPS Next 2Y69.56%
EPS Next 3Y59.2%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.69%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%0.84%
Revenue Next Year25.14%
Revenue Next 2Y38.2%
Revenue Next 3Y39.8%
Revenue Next 5YN/A
EBIT growth 1Y-2199.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year143.94%
EBIT Next 3Y84.08%
EBIT Next 5YN/A
FCF growth 1Y-7.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.85%
OCF growth 3YN/A
OCF growth 5YN/A